Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2009, Article ID 457418, 6 pages
http://dx.doi.org/10.1155/2009/457418
Clinical Study

Non-Cross Resistant Sequential Single Agent Chemotherapy in First-Line Advanced Non-Small Cell Lung Cancer Patients: Results of a Phase II Study

1Department of Pulmonology, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands
2Department of Pulmonology, Amphia Hospital, Breda, The Netherlands
3Department of Pulmonology, St. Franciscus Gasthuis, Rotterdam, The Netherlands
4Department of Pulmonology, St. Antonius, Nieuwegein, The Netherlands
5Department of Trials and Statistics, Erasmus MC-Daniel Den Hoed Cancer Center, Rotterdam, The Netherlands

Received 17 April 2009; Revised 17 July 2009; Accepted 19 August 2009

Academic Editor: James L. Mulshine

Copyright © 2009 V. Surmont et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. V. Scagliotti, P. Parikh, J. von Pawel et al., “Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 26, no. 21, pp. 3543–3551, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. D. Fisher and A. D'Orazio, “Phase II and III trials: comparison of four chemotherapy regimens in advanced non-small cell lung cancer (ECOG 1594),” Clinical Lung Cancer, vol. 2, no. 1, pp. 21–22, 2000. View at Google Scholar
  3. F. Fossella, J. R. Pereira, J. von Pawel et al., “Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group,” Journal of Clinical Oncology, vol. 21, no. 16, pp. 3016–3024, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. T. Le Chevalier, D. Brisgand, and J.-Y. Douillard, “Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 360–367, 1994. View at Google Scholar · View at Scopus
  5. J. H. Schiller, D. Harrington, C. P. Belani et al., “Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer,” The New England Journal of Medicine, vol. 346, no. 2, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. R. S. Day, “Treatment sequencing, asymmetry, and uncertainty: protocol strategies for combination chemotherapy,” Cancer Research, vol. 46, no. 8, pp. 3876–3885, 1986. View at Google Scholar · View at Scopus
  7. L. Norton, “Evolving concepts in the systemic drug therapy of breast cancer,” Seminars in Oncology, vol. 24, no. 4, supplement 10, pp. S10–S3, 1997. View at Google Scholar · View at Scopus
  8. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Google Scholar · View at Scopus
  9. V. Gebbia, D. Galetta, M. Caruso et al., “Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide + gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale,” Lung Cancer, vol. 39, no. 2, pp. 179–189, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. J. Edelman, J. I. Clark, K. Chansky et al., “Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel,” Clinical Cancer Research, vol. 10, no. 15, pp. 5022–5026, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. J. I. Clark, K. Kancharla, R. Qamar et al., “Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer,” Lung Cancer, vol. 34, no. 2, pp. 271–277, 2001. View at Google Scholar · View at Scopus
  12. F. Grossi, O. Belvedere, G. Fasola et al., “Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an alpe-adria thoracic oncology multidisciplinary group study (ATOM 001),” Lung Cancer, vol. 46, no. 1, pp. 99–106, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. K. Kubota, M. Kawahara, M. O. Ogawara et al., “Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study,” The Lancet Oncology, vol. 9, no. 12, pp. 1135–1142, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Feliu, G. Martin, J. Lizon et al., “Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study,” Annals of Oncology, vol. 12, no. 10, pp. 1369–1374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. O. Rixe, M. Gatineau, E. Jauffret et al., “Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC),” Bulletin du Cancer, vol. 92, no. 1, pp. E1–E6, 2005. View at Google Scholar · View at Scopus
  16. C. Manegold, N. Tatcher, C. Kortsik et al., “Sequencing of single-agent (SA) docetaxel (T) and gemcitabine (G) therapy for patients (pts) with advanced non-small cell lung cancer (NSCLC): results of three consecutive randomized trials,” Journal of Clinical Oncology, vol. 24, no. 18s, p. 7035, 2006. View at Google Scholar
  17. A. A. Martoni, F. di Fabio, B. Melotti, S. Giaquinta, and M. Guaraldi, “Planned sequence of gemcitabine followed by vinorelbine in the treatment of elderly patients with advanced non-small cell lung cancer,” Anticancer Research, vol. 26, no. 2B, pp. 1501–1505, 2006. View at Google Scholar · View at Scopus
  18. D. Poon, K. F. Foo, L. Chew, S. S. Leong, J. Wee, and E. H. Tan, “Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer,” Annals of the Academy of Medicine Singapore, vol. 35, no. 1, pp. 33–37, 2006. View at Google Scholar · View at Scopus
  19. V. Hirsh, J. Latreille, H. Kreisman et al., “Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities—a multicenter phase II trial,” Lung Cancer, vol. 49, no. 1, pp. 117–123, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. Tibaldi, E. Vasile, A. Antonuzzo et al., “First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study,” British Journal of Cancer, vol. 98, no. 3, pp. 558–563, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. Vansteenkiste, J. Vandebroek, C. Dooms et al., “Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine,” Lung Cancer, vol. 40, no. 2, pp. 191–199, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. S. W. Lowe, H. E. Ruley, T. Jacks, and D. E. Housman, “P53-dependent apoptosis modulates the cytotoxicity of anticancer agents,” Cell, vol. 74, no. 6, pp. 957–967, 1993. View at Publisher · View at Google Scholar · View at Scopus
  23. W. Akerley, M. Glantz, H. Choy et al., “Phase I trial of weekly paclitaxel in advanced NSCLC,” Journal of Clinical Oncology, vol. 16, no. 1, pp. 153–158, 1998. View at Google Scholar · View at Scopus
  24. W. Akerley, “Paclitaxel in advanced NSCLC,” Chest, vol. 117, pp. 1525–1555, 2000. View at Google Scholar
  25. W. Akerley, J. Herndon, and M. J. Egorin, “CALBG 9731: phase II trial of weekly paclitaxel for advanced NSCLC,” Proceedings of the American Society for Clinical Oncology, vol. 18, p. 462a, 1999. View at Google Scholar
  26. G. D'Addario, M. Pintilie, N. B. Leighl, R. Feld, T. Cerny, and F. A. Shepherd, “Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2926–2936, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. C. Sederholm, G. Hillerdal, K. Lamberg et al., “Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group,” Journal of Clinical Oncology, vol. 23, no. 33, pp. 8380–8388, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. C. P. Belani, T. Brodowicz, T. Ciuleanu et al., “Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC),” Journal of Clinical Oncology, vol. 27, p. 18s, 2009. View at Google Scholar
  29. P. M. Fidias, S. R. Dakhil, A. P. Lyss et al., “Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced NSCLC,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 591–598, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. K. A. Olaussen, A. Dunant, P. Fouret et al., “DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy,” The New England Journal of Medicine, vol. 355, no. 10, pp. 983–991, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. M. Cobo, D. Isla, B. Masuti et al., “Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2747–2754, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. Simon, A. Sharma, X. Li et al., “Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced NSCLC,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2741–2746, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus